EGFR and lung adenocarcinoma: With the advancement of machine learning methods and the continuous development of DL technologies, identifying EGFR mutation status by radiomics in lung adenocarcinoma will continue to be an area of intense clinical medicine research, providing more precise imaging diagnosis and individualized therapeutic guidance for patients.